The p53 protein is among the most effective of the body's natural defences against cancer. News comes of a promising way of releasing the protein from its inhibitions to carry out its anti-tumour duties.
This is a preview of subscription content, log in via an institution to check access.
References
Lane, D. P. & Crawford, L. V. Nature 278, 261–263 (1979).
Vousden, K. H. & Lu, X. Nature Rev. Cancer 2, 594–604 (2002).
Surendran, A. Nature Med. 10, 9 (2004).
Snyder, E. L. et al. PLoS Biol. doi: 10.1371/journal.pbio.0020036 (2004).
Vassilev, L. T. et al. Science 303, 844–848 (2004).
Gudkov, A. V. & Komarova, E. A. Nature Rev. Cancer 3, 117–129 (2003).
Iwakuma, T. & Lozano, G. Mol. Cancer Res. 1, 993–1000 (2003).
Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. Nature 378, 203–206 (1995).
Chene, P. Nature Rev. Cancer 3, 102–109 (2003).
Mendrysa, S. M. et al. Mol. Cell. Biol. 23, 462–473 (2003).
O'Leary, K. A. et al. Mol. Cell. Biol. 24, 186–191 (2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lane, D., Fischer, P. Turning the key on p53. Nature 427, 789–790 (2004). https://doi.org/10.1038/427789a
Issue Date:
DOI: https://doi.org/10.1038/427789a
- Springer Nature Limited
This article is cited by
-
The effect of pre-low-dose X-ray radiation on tumor inhibition of HepG2 cells in tumor-bearing nude mice
The Chinese-German Journal of Clinical Oncology (2012)
-
MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy
Oncogene (2011)
-
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
Nature Chemical Biology (2006)
-
Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53–HDM2 Protein–Protein Interaction
International Journal of Peptide Research and Therapeutics (2006)
-
Wip-ing out cancer
Nature Genetics (2004)